<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 09, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05610475</url>
  </required_header>
  <id_info>
    <org_study_id>20220201</org_study_id>
    <nct_id>NCT05610475</nct_id>
  </id_info>
  <brief_title>Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass</brief_title>
  <acronym>CPB</acronym>
  <official_title>Serum Level of Calpains Product as a Novel Biomarker of Acute Lung Injury Following Cardiopulmonary Bypass(CPB)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Yangzhou University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Yangzhou University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      More than 2 million patients worldwide receive heart surgery every year, majority of these&#xD;
      surgical patients will undergo cardiopulmonary bypass. However, the incidence of&#xD;
      postoperative acute lung injury due to cardiopulmonary bypass is still as high as 20% to 35%.&#xD;
      According to clinical experience, the earlier lung damage is detected, the more successful&#xD;
      the treatment will be. On the basis of traditional detection, the investigators found a new&#xD;
      indicator, serum calpains, which are easy to obtain and have certain specificity.&#xD;
      Importantly, they can predict postoperative acute lung injury within 1 hour after cardiac&#xD;
      surgery. It is meaningful that this indicator can provide clinicians with early&#xD;
      decision-making advice and immediate treatment for patients who may be at risk.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">February 1, 2022</start_date>
  <completion_date type="Actual">August 1, 2022</completion_date>
  <primary_completion_date type="Actual">August 1, 2022</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>PaO2/FiO2 ratio</measure>
    <time_frame>Change from beginning of CPB to 48 h after CPB</time_frame>
    <description>The ratio of inspiratory oxygen fraction to oxygen pressure (PaO2/FiO2) was calculated.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>lung-injury scores</measure>
    <time_frame>The 24 and 48 hours after CPB</time_frame>
    <description>A structured tutorial was used to establish consensus in the interpretation of radiographs for radiographic lung-injury scores, range from 0 to 4.&#xD;
0: No alveolar consolidation; 1: Alveolar consolidation confined to 1 quadrant; 2: Alveolar consolidation confined to 2 quadrants 3: Alveolar consolidation confined to 3 quadrants; 4: Alveolar consolidation in all 4 quadrants.&#xD;
The higher scores mean a worse outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Perioperative serum calpains' concentrations</measure>
    <time_frame>The day before CPB and 1, 12, 24, 48 hours after CPB</time_frame>
    <description>Serial serum samples were obtained and measured by using a fluorometric kit (Abcam, Cambridge, UK) according to the manufacturer's protocol.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Lung Injury, Acute</condition>
  <arm_group>
    <arm_group_label>Lung injury group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Non-lung injury group</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Diagnostic Test</intervention_type>
    <intervention_name>blood cell analysis, blood gas surveillance, chest radiograph and echocardiography</intervention_name>
    <description>Laboratory parameters of all postoperative patients including blood cell analysis, blood gas surveillance, liver, and kidney function alone with chest radiograph and echocardiography were dynamically monitored.</description>
    <arm_group_label>Lung injury group</arm_group_label>
    <arm_group_label>Non-lung injury group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age â‰¥ 18 years;&#xD;
&#xD;
          -  Underwent cardiac surgery using CPB technology.&#xD;
&#xD;
        Exclusion criteria :&#xD;
&#xD;
          -  Patient's lack of consent to participate;&#xD;
&#xD;
          -  Presence of abnormal liver, kidney or other organ function;&#xD;
&#xD;
          -  Pulmonary inflammation, chronic obstructive pulmonary disease or tumors;&#xD;
&#xD;
          -  Underwent cardiac surgery without CPB technology;&#xD;
&#xD;
          -  Postoperative need for extracorporeal membrane oxygenation support.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>the Affiliated Hospital of Yangzhou University</name>
      <address>
        <city>Yangzhou</city>
        <state>Jiangsu</state>
        <zip>225000</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>October 2022</verification_date>
  <study_first_submitted>October 30, 2022</study_first_submitted>
  <study_first_submitted_qc>November 3, 2022</study_first_submitted_qc>
  <study_first_posted type="Actual">November 9, 2022</study_first_posted>
  <last_update_submitted>November 8, 2022</last_update_submitted>
  <last_update_submitted_qc>November 8, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">November 14, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Yangzhou University</investigator_affiliation>
    <investigator_full_name>Zhuan Zhang</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>Cardiopulmonary Bypass</keyword>
  <keyword>Calpain</keyword>
  <keyword>Lung injury</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lung Injury</mesh_term>
    <mesh_term>Acute Lung Injury</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

